34823-86-4

Usage

Uses

1. Used in Pharmaceutical Industry:
1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN is used as a pharmaceutical compound for its potential therapeutic effects. 1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN's unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
2. Used in Chemical Research:
In the field of chemical research, 1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN serves as a valuable compound for studying the properties and behavior of complex organic molecules. Its unique structure can provide insights into the design and synthesis of new compounds with specific applications.
3. Used in Material Science:
1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN may also find applications in material science, where its unique properties can be utilized to develop new materials with specific characteristics. 1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN's potential use in this field is still under exploration and may lead to innovative applications in the future.
4. Used in Class III Receptor Tyrosine Kinase Inhibition:
1-PHENYL-3-H-8-OXA-2,3-DIAZA-CYCLOPENTA[A]INDEN, also known as GTP 14564, is used as a class III receptor tyrosine kinase (RTK) inhibitor. It is effective against various types of kinases, including c-Fms, c-Kit, ITD-FLT3, and PDGFRβ, with IC50s ranging from 0.3 μM to 1 μM. GTP 14564 is used to block the proliferation of leukemia cells stimulated with FLT3 ligand by preventing the activation of STAT5, making it a potential therapeutic agent for certain types of leukemia.

Biological Activity

Potent, selective inhibitor of class III receptor tyrosine kinases (IC 50 values are 0.3 μ M for c-Fms, c-Kit, FLT3 and ITD-FLT3 and 1 μ M for PDGFR β ). Displays no selectivity for ERK1, ERK2, EGFR, MEK1, HER2, Src, Abl, PKC, PKA and Akt (IC50 > 10 μ M). Inhibits FL-dependent proliferation in BaF/ITD-FLT3 cells more potently than BaF/wt-FLT3 cells; anti-leukaemic.

InChI:InChI=1/C15H10N2O/c1-2-6-10(7-3-1)13-15-14(17-16-13)11-8-4-5-9-12(11)18-15/h1-9H,(H,16,17)

Upstream product

• 49615-93-2 (3-aminobenzo[b]furan-2-yl)phenylmethanone 
• 94511-13-4 2-benzoyl-3-p-toluenesulfonylamidobenzofuran 
• 5067-18-5 (3-hydroxybenzofuran-2-yl)(phenyl)methanone 
• 94511-15-6 (Z)-hydrazone of 2-benzoyl-3-p-toluenesulfonylamidobenzofuran 
• 94511-17-8 3-phenyl-8b-p-toluenesulfonylamido-3a,8b-dihydro-1H-benzofuro<3,2-c>pyrazole 

Relevant academic research and scientific papers

Synthesis, cytotoxicities and DNA-binding affinities of benzofuran-3-ols and their fused analogs

A series of benzofuropyrazoles 2a-i were synthesized in 10-92% from the reaction of 2-aroylbenzofuran-3-ols 1a-i with hydrazine hydrate, and screened for their antitumor activities toward four human solid tumor cell lines, including gastric carcinoma cell

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS

Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence.

Tricyclic pyrazole derivatives

This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.

Reaction of 2-acyl-3-aminobenzofurans with hydrazines

While 2-acetyl and 2-benzoyl-3-aminobenzofurans did not react with hydrazine, monomethyl- and N,N-dimethylhydrazine to give the related hydrazones, their 3-N-(p-toluenesulfonyl) derivatives afforded them smoothly in good yields. Depending upon reaction conditions, products arising from hydrazone cyclization to benzofuropyrazoles and/or from furan ring cleavage at the C2-O bond to give 5-(2-hydroxyphenyl)pyrazoles were also formed. The formation of these products depends upon hydrazones configuration and is discussed. Only (E)-isomers appear to undergo furan ring opening. In acidic media at room temperature either the hydrazones or the monomethylhydrazones gave the same related α-azines. Microanalyses, ir, uv, 1H-nmr and ms spectra are in agreement with the proposed structures.